-
Ianalumab: Exploring Its Mechanism, Clinical Applications, and Research Potential(Post)
Quick Facts About IanalumabWhat is Ianalumab?Ianalumab is a monoclonal antibody currently being investigated for its potential in treating autoimmune diseases, particularly lupus and imm
Ulocuplumab: Targeting CXCR4 in Cancer Research and Beyond(Post)Quick Facts About UlocuplumabWhat is Ulocuplumab?Ulocuplumab is an investigational monoclonal antibody targeting CXCR4, a chemokine receptor involved in tumor progression and immune cell
Transmission of SARS-CoV-2 (COVID-19) via Droplets and Aerosols (Post)Transmission of SARS-CoV-2 (COVID-19) via Droplets and Aerosols What is COVID-19? COVID-19, the disea
Lacnotuzumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About LacnotuzumabWhat is Lacnotuzumab?Lacnotuzumab is a monoclonal antibody targeting CD47, a protein that helps cancer cells evade immune system destruction.What is the mec
Antigen Processing & Presentation(Page) Enoblituzumab: Unveiling the Role of Anti-B7-H3 in Cancer Research(Post)Key Facts About EnoblituzumabWhat is Enoblituzumab?Enoblituzumab is a monoclonal antibody targeting the B7-H3 protein, which is expressed on the surface of various cancer cells, includin
Anifrolumab: Transforming Lupus Treatment with Targeted Immunotherapy(Post)Quick Facts About AnifrolumabWhat is Anifrolumab?Anifrolumab is a monoclonal antibody that targets the type I interferon receptor, playing a crucial role in treating systemic lupus eryth
Enokizumab: Exploring Its Mechanism, Clinical Applications, and Biosimilar Advancements(Post)Quick Facts About EnokizumabWhat is Enokizumab?Enokizumab is a monoclonal antibody designed to target interleukin-9 (IL-9), a cytokine involved in inflammatory responses. It has been stu
SfN Neuroscience 2024(Post)SfN 2024: Meet Assay Genie at the Society for NeuroscienceAssay Genie is delighted to be attending SfN 2024 in Chicago, Illinois on 5th to the 9th of October at the McCormick Convention
PD-1/PD-L1 Checkpoint Signalling: Pathway, Function and Assays(Post)PD-1 does not switch a T cell off; it moves the threshold. Engagement of PD-1 by PD-L1 recruits a single phosphatase into the immunological synapse, and that one recruitment event is enough to collap
Nfkb signalling pathway · HTM(Page) High-Fidelity DNA Polymerase(Page) Bevacizumab: Mechanism, Clinical Applications, and Biosimilar Insights(Post)Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne
Avdoralimab: Exploring Its Role in Immunotherapy and Biosimilar Advancements(Post)Quick Facts About AvdoralimabWhat is Avdoralimab?Avdoralimab is a monoclonal antibody targeting C5aR1, playing a crucial role in modulating immune response and inflammation.What is the m
Ipilimumab and Nivolumab: Advancing Research on CTLA-4 in Cancer Therapy(Post)What You Need to Know About IpilimumabWhat is Ipilimumab?Ipilimumab is a monoclonal antibody that targets CTLA-4, a protein involved in downregulating the immune system, to boost the bod
SLAMF7: Activating Natural Killer Cells for Potent Anti-Cancer Responses(Post)Introduction to SLAMF7 in Cancer Immunotherapy SLAMF7, also known as Signaling Lymphocytic Activation Molecule F7, is a surface receptor found on natural killer (NK) cells, T cells, plasm
Crizanlizumab: A Comprehensive Overview of Its Role in Sickle Cell Disease and Ongoing Research(Post)Quick Facts About CrizanlizumabWhat is Crizanlizumab?Crizanlizumab is a monoclonal antibody used to treat sickle cell disease by targeting P-selectin, a protein involved in inflammation
Secukinumab: A Comprehensive Guide to Its Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About SecukinumabWhat is SecukinumabSecukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune respons
CD122: Fine-Tuning T Cell Responses in Immunotherapy(Post)Introduction to CD122 in Immunotherapy CD122, also known as the interleukin-2 receptor beta chain (IL-2Rβ), is a critical component of the immune system's response to pathogens and malign
Allorecognition Pathway: Transplant Rejection, DSA and GvHD(Post)Transplant rejection is the fastest, most violent adaptive immune response a body can mount — and it is a response to a molecule rather than to a pathogen. Somewhere between one and ten per cent of a